切换至 "中华医学电子期刊资源库"

中华心脏与心律电子杂志 ›› 2022, Vol. 10 ›› Issue (03) : 175 -179. doi: 10.3877/cma.j.issn.2095-6568.2022.03.010

所属专题: 总编推荐

综述

合并慢性肾脏疾病的心房颤动患者的治疗
张涛1, 杨艳敏1,()   
  1. 1. 100037 北京,中国医学科学院 北京协和医学院 国家心血管病中心 心血管疾病国家重点实验室 阜外医院急重症中心
  • 收稿日期:2022-06-15 出版日期:2022-09-25
  • 通信作者: 杨艳敏

Management of patients with atrial fibrillation in combination with chronic kidney disease

Tao Zhang1, Yanmin Yang1,()   

  1. 1. Emergency and Intensive Care Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China
  • Received:2022-06-15 Published:2022-09-25
  • Corresponding author: Yanmin Yang
引用本文:

张涛, 杨艳敏. 合并慢性肾脏疾病的心房颤动患者的治疗[J/OL]. 中华心脏与心律电子杂志, 2022, 10(03): 175-179.

Tao Zhang, Yanmin Yang. Management of patients with atrial fibrillation in combination with chronic kidney disease[J/OL]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2022, 10(03): 175-179.

心房颤动(atrial fibrillation,AF)和慢性肾脏病(chronic kidney disease,CKD)存在双向作用。CKD增加AF患者卒中/血栓栓塞风险和出血风险,不同口服抗凝药、左心耳封堵术在合并CKD的AF人群中的有效性及安全性尚需更多研究数据支持。是否合并CKD不影响AF患者心率控制或节律控制策略的选择,而导管消融的有效性和安全性数据尚不充分。本文就合并CKD的AF人群抗凝策略、心率控制或节律控制策略等方面的研究进展做一综述。

表1 几种出血风险评分模型纳入的危险因素
表2 常用心率/节律控制药物代谢参数及肾功能不全时剂量调整建议
[1]
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11):825-830.
[2]
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association[J]. Circulation, 2019, 139(10):e56-e528.
[3]
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225):709-733.
[4]
Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease[J]. Circulation, 2013, 127(5):569-574.
[5]
Ding WY, Gupta D, Wong CF, et al. Pathophysiology of atrial fibrillation and chronic kidney disease[J]. Cardiovasc Res, 2021, 117(4):1046-1059.
[6]
Landray MJ, Wheeler DC, Lip GY, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study[J]. Am J Kidney Dis, 2004, 43(2):244-253.
[7]
Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation[J]. Circulation, 2001, 104(24):2886-2891.
[8]
Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease[J]. Pharmacol Rev, 2007, 59(3):251-287.
[9]
Goette A, Staack T, Röcken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation[J]. J Am Coll Cardiol, 2000, 35(6):1669-1677.
[10]
Heijman J, Voigt N, Ghezelbash S, et al. Calcium handling abnormalities as a target for atrial fibrillation therapeutics: how close to clinical implementation?[J]. J Cardiovasc Pharmacol, 2015, 66(6):515-522.
[11]
Chen WT, Chen YC, Hsieh MH, et al. The uremic toxin indoxyl sulfate increases pulmonary vein and atrial arrhythmogenesis[J]. J Cardiovasc Electrophysiol, 2015, 26(2):203-210.
[12]
Yamagami F, Tajiri K, Yumino D, et al. Uremic toxins and atrial fibrillation: mechanisms and therapeutic implications[J]. Toxins (Basel), 2019, 11(10):597.
[13]
Umana E, Ahmed W, Alpert MA. Valvular and perivalvular abnormalities in end-stage renal disease[J]. Am J Med Sci, 2003, 325(4):237-242.
[14]
Chen SC, Su HM, Hung CC, et al. Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease[J]. Clin J Am Soc Nephrol, 2011, 6(12):2750-2758.
[15]
Pisters R, Lane DA, Marin F, et al. Stroke and thromboembolism in atrial fibrillation[J]. Circ J, 2012, 76(10):2289-2304.
[16]
Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease[J]. N Engl J Med, 2012, 367(7):625-635.
[17]
Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study[J]. J Am Coll Cardiol, 2014, 64(23):2471-2482.
[18]
Yahalom G, Schwartz R, Schwammenthal Y, et al. Chronic kidney disease and clinical outcome in patients with acute stroke[J]. Stroke, 2009, 40(4):1296-1303.
[19]
Kerr KF, Wang Z, Janes H, et al. Net reclassification indices for evaluating risk prediction instruments: a critical review[J]. Epidemiology, 2014, 25(1):114-121.
[20]
Abumuaileq RR, Abu-Assi E, López-López A, et al. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation[J]. BMC Cardiovasc Disord, 2015, 15:156.
[21]
Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review[J]. Thromb Haemost, 2018, 118(12):2171-2187.
[22]
Huang KW, Leu HB, Luo JC, et al. Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis[J]. Dig Dis Sci, 2014, 59(4):807-813.
[23]
Zulkifly H, Lip GYH, Lane DA. Bleeding risk scores in atrial fibrillation and venous thromboembolism[J]. Am J Cardiol, 2017, 120(7):1139-1145.
[24]
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
[25]
Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K Anticoagulant Agents in patients with advanced chronic kidney disease or on dialysis with AF[J]. J Am Coll Cardiol, 2016, 67(24):2888-2899.
[26]
He W, Zhang H, Zhu W, et al. Effect of anticoagulation therapy in older patients with chronic kidney disease and atrial fibrillation: a meta-analysis[J]. Medicine (Baltimore), 2019, 98(42):e17628.
[27]
Yang F, Hellyer JA, Than C, et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease[J]. Heart, 2017, 103(11):818-826.
[28]
Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission?[J]. JAMA, 2014, 311(9):913-915.
[29]
Chan PH, Huang D, Yip PS, et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis[J]. Europace, 2016, 18(5):665-671.
[30]
Bai Y, Chen H, Yang Y, et al. Safety of antithrombotic drugs in patients with atrial fibrillation and non-end-stage chronic kidney disease: Meta-analysis and systematic review[J]. Thromb Res, 2016, 137:46-52.
[31]
Malhotra K, Ishfaq MF, Goyal N, et al. Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis[J]. Neurology, 2019, 92(21):e2421-e2431.
[32]
Siltari A, Vapaatalo H. Vascular calcification, vitamin K and warfarin therapy - possible or plausible connection? [J]. Basic Clin Pharmacol Toxicol, 2018, 122(1):19-24.
[33]
Chen J, Budoff MJ, Reilly MP, et al. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease[J]. JAMA Cardiol, 2017, 2(6):635-643.
[34]
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12):1139-1151.
[35]
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011, 365(10):883-891.
[36]
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11):981-992.
[37]
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013, 369(22):2093-2104.
[38]
Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of Apixaban compared with Warfarin in patients with atrial fibrillation in relation to renal function over time: Insights from the ARISTOTLE randomized clinical trial[J]. JAMA Cardiol, 2016, 1(4):451-460.
[39]
Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis[J]. Circulation, 2015, 131(11):972-979.
[40]
Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis[J]. Circulation, 2015, 131(11):972-979.
[41]
Kuno T, Takagi H, Ando T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis[J]. J Am Coll Cardiol, 2020, 75(3):273-285.
[42]
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons[J]. Circulation, 2019, 140(2):e125-e151.
[43]
Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF Trials[J]. J Am Coll Cardiol, 2017, 70(24):2964-2975.
[44]
Li M, Liu T, Luo D, et al. Systematic review and meta-analysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation[J]. Cardiol J, 2014, 21(1):89-95.
[45]
Boriani G, Savelieva I, Dan GA, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society[J]. Europace, 2015, 17(8):1169-1196.
[46]
Li M, Liu T, Luo D, Li G. Systematic review and meta-analysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation[J]. Cardiol J, 2014, 21(1):89-95.
[47]
王静, 沈尤美, 郦明芳,等. 肾功能不全对肺静脉前庭隔离术治疗阵发性心房颤动的影响[J].南京医科大学学报, 2019,(11):1605-1608.
[48]
Navaravong L, Barakat M, Burgon N, et al. Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2015, 26(1):21-27.
[49]
Diemberger I, Genovesi S, Massaro G, et al. Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease[J]. Curr Pharm Des, 2018, 24(24):2794-2801.
[1] 周正阳, 陈凯, 仇多良, 邵乐宁, 吴浩荣, 钟丰云. 腹腔镜腹股沟疝修补术后出血原因分析及处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 660-664.
[2] 杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[3] 程柏凯, 杨光. 高胰岛素-正葡萄糖钳夹技术评估慢性肾脏病患者胰岛素抵抗的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 334-339.
[4] 王永楠, 汤畅通, 殷杰, 谭溢涛. 微创钻孔引流术与神经内镜血肿清除术治疗临界量基底节脑出血的效果对比分析[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 286-292.
[5] 张志超, 李陈, 韩惠, 周夏, 洪家康. 经额平行白质纤维束立体定向血肿穿刺引流术与神经内镜下血肿清除术治疗基底节脑出血的临床对比分析[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 299-303.
[6] 吴广迎, 张延娟, 秦鹏, 卢艳丽. 经颈静脉肝内门体静脉分流术预防上消化道出血的临床研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 545-548.
[7] 于洁, 金小红, 顾艳楣, 王慧, 葛杨杨, 李燕. 癌症相关静脉血栓栓塞症患者疾病体验与需求的质性研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 739-744.
[8] 董晟, 郎胜坤, 葛新, 孙少君, 薛明宇. 反向休克指数乘以格拉斯哥昏迷评分对老年严重创伤患者发生急性创伤性凝血功能障碍的预测价值[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 541-547.
[9] 奚培培, 周加军. 慢性肾脏病患者肌少症机制和诊治的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 491-495.
[10] 耿晓坤. 缺血性卒中后无效再灌注的时间窗、组织窗与神经保护[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(06): 636-636.
[11] 郑屹, 刘莹, 张煜坤, 李广平, 陈康寅, 刘彤. 既往及新发心房颤动对急性心肌梗死患者远期卒中风险的影响[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 406-417.
[12] 刘志超, 胡风云, 温春丽. 山西省脑卒中危险因素与地域的相关性分析[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 424-433.
[13] 王丽娜, 吕书霞, 李亚男. 脑卒中偏瘫患者健康焦虑元认知与疾病接受度、恐惧疾病进展的相关性[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 434-440.
[14] 穆巴拉克·伊力哈, 徐霁华, 鲁明. 急性轻型卒中微量脑出血误诊病例的临床特点及影像学表现分析[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 441-445.
[15] 赵伟伟, 赵玉华, 刘小璇. 西藏地区亚甲基四氢叶酸还原酶C677T多态性及其与脑微出血的相关性[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 473-478.
阅读次数
全文


摘要